The biotech industry is on the brink of a significant transformation, driven by advancements in genetic validation, data-centric investment strategies, and the integration of real-world data (RWD) in clinical trials. By 2025, these innovations are expected to revolutionize cardiovascular research
MilliporeSigma, the Life Science business of Merck KGaA in the U.S. and Canada, has announced a definitive agreement to acquire HUB Organoids Holding B.V. (HUB). This acquisition marks a significant step forward in enhancing their 2D and 3D cell culture portfolio with the innovative technology of
The intricate relationship between our gut microbiota and the risk of developing colon cancer has captivated scientific interest recently, revealing new layers of complexity in how our body's internal systems interact. Researchers at the University of Wisconsin-Madison have discovered that
In the quest to understand the intricate relationships between the gut microbiome and our overall health, researchers from the University of Wisconsin-Madison have uncovered a significant connection between specific microbially-modified bile acids and colorectal cancer risk. This groundbreaking
A groundbreaking study led by Natasha Chang at McGill University has shown that a novel drug, K884, holds promise for treating Duchenne muscular dystrophy (DMD), a devastating genetic disorder characterized by severe muscle degeneration. Unlike conventional treatments, which primarily focus on
The recent discovery by researchers at the University of California San Diego (UCSD) has shed light on why previous vaccines against Staphylococcus aureus (S. aureus) have failed in human trials despite success in mouse models. This breakthrough could pave the way for effective vaccines against
